surmount studies tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Tirzepatide for Obesity Treatment and

The American Diabetes Association emphasizes that good glycemic control itself is protective against cognitive decline, making effective diabetes management a priority for long-term brain health

A3: Epimedium is used as a prime drug to combat erectile dysfunction in men and frigidity in women

Its main job is to target the MC1R receptor in skin cells called melanocytes

If eGFR is below 60 mL/min/1.73m, creatine supplementation is generally not recommended, regardless of GLP-1 use

CAPE blocks IKK phosphorylation, preventing NF-B nuclear translocation and cytokine expression (100)

Cantitatea de Omega-3 este mai important dect raportul su fa de Omega-6 4